APVO
NASDAQ · Biotechnology
Aptevo Therapeutics Inc
$6.70
+0.69 (+11.48%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.10M | 989.8K | 1.05M |
| Net Income | -234,853 | -218,932 | -208,731 |
| EPS | — | — | — |
| Profit Margin | -21.4% | -22.1% | -19.9% |
| Rev Growth | -6.5% | +19.5% | +20.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.28M | 2.80M | 2.55M |
| Total Equity | 2.39M | 2.45M | 2.40M |
| D/E Ratio | 0.95 | 1.14 | 1.06 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -290,262 | -298,722 | -291,498 |
| Free Cash Flow | -192,766 | -116,937 | -167,359 |